MedTrace Logo

Impact of a Reminder App on Physical Activity During Radiation Therapy for Lung Cancer

NCT07627022 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-06-04

No results posted yet for this study

Summary

The primary objective of this prospective randomized trial is to explore whether the use of a smart phone-based reminder application is associated with a change in physical activity during radiation therapy in patients with lung cancer. The primary endpoint focuses on the within-patient change in physical activity between Week 1 and Week 5, with comparison between treatment groups to assess potential differences attributable to the intervention.

Secondary objectives include the exploratory assessment of patient satisfaction with the reminder app, its impact on the use and perception of digital health technology.

A total of 28 evaluable patients in the Full Analysis Set (approximately 14 per treatment arm) are required to detect a clinically relevant difference corresponding to a probability of superiority of approximately 0.65 with 80% power at a two-sided significance level of 0.05. Assuming that approximately 10% of patients will not be evaluable for the primary endpoint, a total of 32 patients will be randomized.

Conditions

Interventions

DEVICE

mobile application (reminder app)

Mobile application (reminder app) that reminds patients three to four times daily to walk a pre-defined number of steps.

RADIATION

Standard radiotherapy

Patients receive standard radiotherapy or radio-chemotherapy for lung cancer.

Sponsors & Collaborators

  • European Regional Development Fund

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • Dirk Rades, Prof. Dr. · Department of Radiation Oncology, University of Luebeck, Germany

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-02-15
Completion
2027-02-15

Countries

  • Denmark
  • Georgia
  • Germany
  • Slovenia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07627022 on ClinicalTrials.gov